Prev Next

BP-C1 Oncology


BP-C1 is a unique product that clinically has proven to have both strong palliation properties as well as tumor control properties. .....read more

BP-C2 Radiation Defence


BP-C2 incorporates immunomodulating and chelating ligand and a molybdenum, needed for detoxification. .....read more

BP-C1 Oncology


BP-C1 is a unique product that clinically has proven to have both strong palliation properties as well as tumor control properties. .....read more

BP-C1

Game change in Oncology

BP-C1 is a novel product based on Meabco’s patented technology platform. BP-C1 acts strongly apoptotic, anti-proliferative and anti-angiogenic on tumor cells, whilst having immunomodulating properties.


Our clinical trials show:

  • 86% tumor growth control response in stage 4 MBC patients
  • High safety profile
  • Negligible side-effects
  • Marked improvements on Quality of Life
  • Normalization of abnormal blood values

 

BP-C1 opens up for home care and de-centralized treatment. It is furthermore economical in cost and potentially eliminates concomitant medication and treatment. Thus, treatment with BP-C1 potentiates increased accessibility to cancer treatment as well as huge socio-economic savings.

 

Effective in most solid and hematological tumors in cell line studies, BP-C1 offers great potential in the treatment of a large variety of cancers. Furthermore, we see possibilities of BP-C1 as monotherapy as well as in combinations with other cancer drugs and treatments.

 


MEABCO A/S  |  Richard Mortensens Vej 61  |  DK-2300 Copenhagen  |  Telephone: +45 32 46 03 70  | e-mail: info@meabco.com
Websitet anvender cookies til at huske dine indstillinger, statistik og at målrette annoncer. Når du besøger vores hjemmeside, accepterer du automatisk vores brug af Cookies.